Integrin Signaling Modulation Therapy for Neurodegeneration

📖 Wiki Page

idea814 wordssynced 2026-04-02

Integrin Signaling Modulation Therapy for Neurodegeneration

Overview

flowchart TD ideas_payload_integrin_signali["Integrin Signaling Modulation Therapy for Neurod"] ideas_payload_integrin_signali["represents"] ideas_payload_integrin_signali -->|"related to"| ideas_payload_integrin_signali style ideas_payload_integrin_signali fill:#81c784,stroke:#333,color:#000 ideas_payload_integrin_signali["novel"] ideas_payload_integrin_signali -->|"related to"| ideas_payload_integrin_signali style ideas_payload_integrin_signali fill:#81c784,stroke:#333,color:#000 ideas_payload_integrin_signali["approach"] ideas_payload_integrin_signali -->|"related to"| ideas_payload_integrin_signali style ideas_payload_integrin_signali fill:#81c784,stroke:#333,color:#000 ideas_payload_integrin_signali["targeting"] ideas_payload_integrin_signali -->|"related to"| ideas_payload_integrin_signali style ideas_payload_integrin_signali fill:#81c784,stroke:#333,color:#000 style ideas_payload_integrin_signali fill:#4fc3f7,stroke:#333,color:#000

Integrin Signaling Modulation Therapy represents a novel approach targeting the integrin signaling pathway to restore synaptic function, enhance neuroprotection, and modulate microglial phagocytosis in neurodegenerative diseases. Integrins are heterodimeric transmembrane receptors that connect the extracellular matrix to the intracellular cytoskeleton, playing critical roles in cell adhesion, migration, survival, and synaptic plasticity.

Biological Background

...

Integrin Signaling Modulation Therapy for Neurodegeneration

Overview

Mermaid diagram (expand to render)

Biological Background

Integrin Family in the CNS

The central nervous system expresses multiple integrin heterodimers with distinct functions:

α5β1 integrin: Primary fibronectin receptor, regulates neuronal migration and synaptic formation
α6β1/β4 integrins: Laminin receptors, essential for neurite outgrowth and myelination
αvβ3 integrin: Vitronectin receptor, implicated in synaptic plasticity and memory formation
α4β1 (VLA-4): Leukocyte integrin mediating immune cell infiltration
αMβ2 (Mac-1): Microglial integrin regulating phagocytosis

Integrin Signaling in Neurodegeneration

Integrin signaling is perturbed in multiple neurodegenerative conditions:

Alzheimer's disease: Altered integrin expression on neurons and glia; β1 integrin reductions correlate with synaptic loss

Parkinson's disease: α-synuclein interacts with integrins to promote microglial activation and neuron-to-neuron propagation

ALS: Integrin alterations affect neuromuscular junction stability and astrocyte-neuron communication

Therapeutic Mechanisms

1. Synaptic Integrity Restoration

β1 integrin stabilization: Promote synaptic spine formation and maintenance
FAK modulation: Enhance downstream survival signaling (PI3K/Akt, MAPK)
Actin cytoskeleton remodeling: Restore dendritic spine morphology

2. Microglial Phagocytosis Modulation

αMβ2 (Mac-1) modulation: Fine-tune microglial clearance of debris and protein aggregates
Integrin-αvβ3 targeting: Modulate microglial inflammatory response

3. Blood-Brain Barrier Interactions

α4β1 antagonism: Reduce pathological immune cell infiltration
Pericyte-integrin signaling: Preserve BBB integrity

Target Product Profile

| Attribute | Specification |
|-----------|---------------|
| Primary Target | α5β1, αvβ3, αMβ2 integrins |
| Modality | Small molecule or antibody |
| Delivery | Systemic with BBB penetration |
| Patient Population | Early-to-moderate AD, PD, ALS |

Rubric Scores (10-Dimension)

| Dimension | Score | Rationale |
|-----------|-------|----------|
| Novelty | 8 | Integrin targeting in neurodegeneration is underexplored |
| Mechanistic Rationale | 8 | Integrins link ECM to neuronal survival; documented alterations in AD/PD |
| Root-Cause Coverage | 7 | Addresses synaptic dysfunction and neuroinflammation |
| Delivery Feasibility | 6 | BBB penetration remains challenging |
| Safety Plausibility | 7 | Integrin modulators have shown acceptable profiles in oncology |
| Combinability | 8 | Synergistic with anti-amyloid, anti-inflammatory approaches |
| Biomarker Availability | 6 | CSF integrin fragments as potential markers |
| De-risking Path | 7 | Clear readouts in preclinical models |
| Multi-disease Potential | 9 | Strong rationale across AD, PD, ALS |
| Patient Impact | 7 | Addresses fundamental synaptic deficits |

Total Score: 73/100

Disease Coverage

| Disease | Coverage Score | Priority |
|---------|---------------|----------|
| Alzheimer's Disease | 8 | Primary |
| Parkinson's Disease | 7 | Secondary |
| ALS | 6 | Secondary |
| FTD | 5 | Tertiary |
| Aging | 7 | Prevention |

Implementation Strategy

Preclinical Development

In vitro: Test integrin modulators on neuronal cultures, astrocyte-neuron co-cultures

In vivo: Use integrin-knockout or transgenic models (e.g., β1 conditional KO)

Efficacy endpoints: Synaptic marker expression, behavioral testing, microglia morphology

Clinical Development

Phase I: Safety in healthy volunteers (similar to integrin antagonists in oncology)

Phase II: Proof-of-concept in early AD/PD patients

Biomarkers: CSF integrin fragments, synaptic PET ligands

De-risking Path

Year 1: Identify lead compounds from integrin modulator libraries
Year 2: Preclinical GLP toxicology and IND-enabling studies
Year 3: Phase I clinical trials
Year 4-5: Phase II efficacy trials with synaptic biomarkers

Risks and Mitigation

| Risk | Likelihood | Mitigation |
|------|------------|------------|
| Off-target effects | Moderate | Selective compound optimization |
| BBB penetration | High | Focus on small molecule approaches |
| Immunogenicity | Low | Use small molecules over antibodies |
| Integrin redundancy | Moderate | Target multiple integrin subtypes |

Actionable Next Steps

Literature review: Deep dive into integrin alterations in AD/PD post-mortem tissue

Compound screening: Partner with oncology integrin programs for CNS repurposing

Biomarker development: Establish CSF integrin fragment assay

Academic collaboration: Connect with integrins-in-CNS researchers

Cross-Links

[Microglia Pathway](/mechanisms/ad-neuroinflammation-microglia-pathway)
[Synaptic Plasticity](/mechanisms/activity-dependent-synaptic-plasticity)
[FAK Inhibition Therapy](/ideas/payload-fak-inhibition-neurodegeneration) — complementary mechanism
[TAM Receptor Modulation](/ideas/payload-tam-receptor-modulation-therapy) — complementary phagocytosis target

External Links

[Integrins and neurological disorders - PubMed](https://pubmed.ncbi.nlm.nih.gov/23685833/)
[Integrins as drug targets in CNS - PubMed](https://pubmed.ncbi.nlm.nih.gov/22145555/)

References

[Mommersteeg MC, Donnan G, Humpel C, et al, Integrins in the CNS and their role in dementia (2013)](https://pubmed.ncbi.nlm.nih.gov/23685833/)

[Wu X, Reddy DS, Integrins as receptor targets for neurological disorders (2012)](https://pubmed.ncbi.nlm.nih.gov/22145555/)

[Chan CS, Weisman GA, Kayali G, et al, Integrin alterations in Alzheimer's disease and response to immunotherapy (2010)](https://pubmed.ncbi.nlm.nih.gov/20097276/)

[Krammer C, Isenmann S, Brandner S, et al, The role of integrins in alpha-synuclein toxicity in multiple system atrophy and Parkinson's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31016685/)

📖 View canonical wiki page →

Integrin Signaling Modulation Therapy for Neurodegeneration

Integrin Signaling Modulation Therapy for Neurodegeneration

Overview

Biological Background

Integrin Signaling Modulation Therapy for Neurodegeneration

Overview

Biological Background

Integrin Family in the CNS

Integrin Signaling in Neurodegeneration

Therapeutic Mechanisms

1. Synaptic Integrity Restoration

2. Microglial Phagocytosis Modulation

3. Blood-Brain Barrier Interactions

Target Product Profile

Rubric Scores (10-Dimension)

Disease Coverage

Implementation Strategy

Preclinical Development

Clinical Development

De-risking Path

Risks and Mitigation

Actionable Next Steps

Cross-Links

See Also

External Links

References